Antengene to Unveil Groundbreaking Preclinical Data on ATG-207 at EULAR 2026
Antengene Corporation is set to present its first preclinical data on ATG-207, a novel bifunctional fusion protein targeting autoimmune diseases, at the upcoming EULAR 2026 conference. This development marks a significant step forward in the treatment of conditions like systemic lupus erythematosus and rheumatoid arthritis.